|Articles|February 1, 2005

Imiquimod may potentiate melanoma vaccine effect

Newport Beach, Calif. — The immune response modifier imiquimod (Aldara, 3M Pharmaceuticals) may have a role as an enhancer of other immunotherapies for melanoma, Noah Craft, M.D., Ph.D. said here at the annual meeting of the Pacific Dermatologic Association (PDA).

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME